How to appeal an Aetna pediatric epilepsy denial
ACA §2719 + ERISA §503 · 180-day window · 30-day decision
To appeal an Aetna pediatric epilepsy denial, file an internal appeal within 180 days of the date on the denial letter through Aetna's member or provider portal, under ACA §2719 + ERISA §503. Aetna returns standard decisions in 30 days; if it upholds the denial you can request an independent external review within 4 months.
The framework that applies to your appeal
Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.
Aetna-specific note: Owned by CVS Health since 2018. CVS Caremark is the PBM. Aetna ASA administers self-funded ERISA plans. Meritain Health is Aetna's TPA brand.
What Aetna's policy requires for pediatric epilepsy
Cited policy: Aetna Fintepla (Fenfluramine) Clinical Policy Bulletin
Dravet syndrome (>=2 yr per Jun 2020 label) OR LGS (>=2 yr per Mar 2022 label). Diagnosis confirmed by pediatric epileptologist. Failed >=2 appropriate AEDs (clobazam + valproate typical). Enrolled in Fintepla REMS — baseline echocardiogram + q6mo through treatment + 3-6 mo post-d/c (cardiac valvulopathy + PAH monitoring). Not used with MAOI or within 14 d. Reauth at 6 mo with >=30% seizure reduction.
How Aetna denies pediatric epilepsy — and how to counter it
Where Aetna pushes back: 1) Fenfluramine cardiac history concern (Fen-Phen 1997 withdrawal); 2) Try Diacomit / Epidiolex first; 3) Echo monitoring infrastructure not in place.
Counter-arguments that hold up: Fintepla approved Jun 25, 2020 Dravet + Mar 22, 2022 LGS. Pediatric epilepsy dosing 0.2-0.7 mg/kg/d (max 26 mg/d) — far below historical Fen-Phen anorectic doses (60-120 mg/d). REMS w/ q6mo echo addresses cardiac risk. Study 1502 Lagae Lancet 2019 — 62.3% greater convulsive-seizure reduction vs placebo at 0.7 mg/kg/d, ZERO valvulopathy/PAH. Study 1601 Knupp Lancet Neurol 2022 LGS supportive. Open-label extension Sullivan Epilepsia 2025 — long-term safety confirmed across 5+ yr. Parallel pathway with Epidiolex / Diacomit (additive efficacy in Dravet — Lagae 2018 OLE).
What Aetna typically denies for pediatric epilepsy
Across Aetna's commercial and Medicare books, denials cluster around a small number of patterns. For pediatric epilepsy, expect:
- UM-2575 medical necessity denials
- Prior auth absent
- Step therapy on specialty drugs
- Out-of-network ER reduction
Treatments most often denied in this category
These are the pediatric epilepsy treatments most often flagged for prior auth, step therapy, or medical necessity review:
- Epidiolex
- Fintepla
- Diacomit
- Clobazam (Onfi/Sympazan)
- Banzel
- Ztalmy (CDKL5)
How to submit the appeal to Aetna
- Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
- Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Aetna cited in the denial.
- File the appeal through Aetna's portal (members: https://www.aetna.com ; providers: https://www.aetnaprovider.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
- If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In CT, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.
Clinician or prior-auth team handling this on the practice side? See Aetna's prior-authorization criteria by drug: Aetna PA criteria on ApprovalHelp.
Frequently asked questions
How long do I have to appeal an Aetna pediatric epilepsy denial?
Aetna allows 180 days from the date on the denial letter to file an internal appeal. Standard decisions come back within 30 days; expedited decisions for urgent care typically within 72 hours.
What's the fastest way to submit an Aetna appeal?
Members can submit through the Aetna member portal at https://www.aetna.com. Providers should use the provider portal at https://www.aetnaprovider.com. Faxed and mailed appeals are accepted but take longer.
What denials does Aetna most often issue for pediatric epilepsy?
For pediatric epilepsy, Aetna most often denies on: 1) Fenfluramine cardiac history concern (Fen-Phen 1997 withdrawal); 2) Try Diacomit / Epidiolex first; 3) Echo monitoring infrastructure not in place. The strongest counters: Fintepla approved Jun 25, 2020 Dravet + Mar 22, 2022 LGS. Pediatric epilepsy dosing 0.2-0.7 mg/kg/d (max 26 mg/d) — far below historical Fen-Phen anorectic doses (60-120 mg/d). REMS w/ q6mo echo addresses cardiac risk. Study 1502 Lagae Lancet 2019 — 62.3% greater convulsive-seizure reduction vs placebo at 0.7 mg/kg/d, ZERO valvulopathy/PAH. Study 1601 Knupp Lancet Neurol 2022 LGS supportive. Open-label extension Sullivan Epilepsia 2025 — long-term safety confirmed across 5+ yr. Parallel pathway with Epidiolex / Diacomit (additive efficacy in Dravet — Lagae 2018 OLE).
What if Aetna denies the appeal too?
After an internal appeal denial you have the right to an external review by an independent reviewer (IRO) — request it within 4 months of the final internal denial.
Related appeal guides
Start your Pediatric epilepsy appeal
Upload your Aetna denial letter — DenialHelp drafts a physician-ready appeal in five minutes, aligned to ACA §2719 + ERISA §503.
Get started →Contact: hello@denialhelp.com